How to buy Larimar Therapeutics stock (LRMR)

Larimar Therapeutics is a biotechnology business based in the US. Larimar Therapeutics shares (LRMR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.96 – a decrease of 1.25% over the previous week. Larimar Therapeutics employs 42 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Larimar Therapeutics stock

Buy Larimar Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Larimar Therapeutics stock price (NASDAQ: LRMR)

Use our graph to track the performance of LRMR stocks over time.

Larimar Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$3.96
52-week range	$3.01 - $13.68
50-day moving average more info button	$6.79
200-day moving average more info button	$7.55
Wall St. target price	$20.41
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.15

Is it a good time to buy Larimar Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Larimar Therapeutics price performance over time

Historical closes compared with the close of $3.995 from 2024-12-26

1 week (2024-12-20)	-0.37%
1 month (2024-11-27)	-39.83%
3 months (2024-09-27)	-39.19%
6 months (2024-06-27)	-45.65%

1 year (2023-12-27)	-15.18%
2 years (2022-12-27)	0.38%
3 years (2021-12-27)	10.26
5 years (2019-12-27)	13.92

Larimar Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-28.55%
Return on equity TTM	-44.5%
Profit margin	0%
Book value	$3.11
Market Capitalization more info button	$241.2 million

TTM: trailing 12 months

Larimar Therapeutics share dividends

We're not expecting Larimar Therapeutics to pay a dividend over the next 12 months.

Have Larimar Therapeutics's shares ever split?

Larimar Therapeutics's shares were split on a 1:12 basis on 28 May 2020 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Larimar Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Larimar Therapeutics shares which in turn could have impacted Larimar Therapeutics's share price.

Larimar Therapeutics share price volatility

Over the last 12 months, Larimar Therapeutics's shares have ranged in value from as little as $3.01 up to $13.68. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Larimar Therapeutics's is 0.713. This would suggest that Larimar Therapeutics's shares are less volatile than average (for this exchange).

Larimar Therapeutics overview

Larimar Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. .

Frequently asked questions

What percentage of Larimar Therapeutics is owned by insiders or institutions?
Currently 1.45% of Larimar Therapeutics shares are held by insiders and 106.564% by institutions. How many people work for Larimar Therapeutics?
Latest data suggests 42 work at Larimar Therapeutics. When does the fiscal year end for Larimar Therapeutics?
Larimar Therapeutics's fiscal year ends in December. Where is Larimar Therapeutics based?
Larimar Therapeutics's address is: Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004 What is Larimar Therapeutics's ISIN number?
Larimar Therapeutics's international securities identification number is: US5171251003